Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors
Premenopausal patients with breast cancer treated with aromatase inhibitors and ovarian suppression may be at elevated risk for CVD and should be monitored for cardiovascular risk.
Authors
- Elizabeth J. Polter (ORCID: https://orcid.org/0000-0001-7336-3492)
- Anne Hudson Blaes (ORCID: https://orcid.org/0000-0002-5433-4810)
- Anna E. Prizment (ORCID: https://orcid.org/0000-0001-5924-6871)
- Pamela L. Lutsey (ORCID: https://orcid.org/0000-0002-1572-1340)
- Rob F. Walker (ORCID: https://orcid.org/0000-0002-1151-3675)
- Wendy Wang (ORCID: https://orcid.org/0000-0001-6025-0173)
- Zoe Ryan
Institutions
- University of Minnesota (US)
- University of Minnesota Medical Center (US)
- Minnesota Oncology (US)
Publication Details
- Journal
- JACC CardioOncology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1016/j.jaccao.2024.08.006
- Citations
- 12
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 4.82
Funders
- National Institutes of Health